전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
CGTAAVStandard DatabasestaleMeiraGTx UK II LtdPhase 2

AAV RPE65 (AAV RPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 5Status Active
CGTAAVLimited DatastaleMeiraGTx UK II LtdPreclinical

AAV OPTIRPE65 (AAV OPTIRPE65)

Leber Congenital Amaurosis (LCA); Eye Diseases · Leber Congenital Amaurosis (LCA)

#LeberCongenitalAmaurosisLCA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeacon TherapeuticsPhase 2

rAAV2-CB-hRPE65 (rAAV2-CB-hRPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

rAAV2-CBSB-hRPE65 (rAAV2-CBSB-hRPE65)

Amaurosis of Leber; Retinal Diseases · Amaurosis of Leber

#AmaurosisofLeber#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNantes University HospitalPhase 2

rAAV2/4.hRPE65 (rAAV2/4.hRPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active